HAIC Clinical Trials
15 recruitingProcedure
Phase 210Not Applicable2Phase 31
Showing 1–15 of 15 trials
Recruiting
Phase 2
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Biliary Tract Cancer
Air Force Military Medical University, China124 enrolled1 locationNCT07569679
Recruiting
Phase 2
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
HCC - Hepatocellular CarcinomaConversion Therapy
Tianjin Medical University Cancer Institute and Hospital43 enrolled1 locationNCT07560488
Recruiting
Phase 2
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Hepatocellular Carcinoma (HCC)
Fudan University164 enrolled1 locationNCT06860490
Recruiting
Phase 2
HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Advanced CancerICC
Eastern Hepatobiliary Surgery Hospital50 enrolled1 locationNCT07364305
Recruiting
Phase 2
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
HCC - Hepatocellular Carcinoma
Peking Union Medical College Hospital300 enrolled1 locationNCT07157969
Recruiting
Not Applicable
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Li Qiang286 enrolled1 locationNCT07070076
Recruiting
Phase 2
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
Mixed Hepatocellular-cholangiocarcinoma
Fudan University45 enrolled1 locationNCT07105748
Recruiting
Not Applicable
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Nanjing Tianyinshan Hospital300 enrolled1 locationNCT06893887
Recruiting
Phase 2
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
HCC
Lei ZHAO40 enrolled1 locationNCT06904014
Recruiting
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Liver CancerHepatocellular CarcinomaHepatic Chemotherapy
Sun Yat-sen University664 enrolled1 locationNCT06641713
Recruiting
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD300 enrolled2 locationsNCT05713994
Recruiting
Phase 2
Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Tongji Hospital36 enrolled1 locationNCT06187961
Recruiting
Phase 2
Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma Non-resectable
Tongji Hospital36 enrolled1 locationNCT06192797
Recruiting
Phase 2
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
Intrahepatic Cholangiocarcinoma
Lei ZHAO20 enrolled1 locationNCT06296563
Recruiting
Phase 3
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Hepatocellular Carcinoma
Sun Yat-sen University300 enrolled3 locationsNCT05476432